Opinion|Videos|April 10, 2025
Practical Realities of CAR T-Cell Therapy for R/R DLBCL: Challenges and Lessons From the Community
Author(s)Rita Assi, MD , Girish Kunapareddy, MD
Experts discuss the main operational challenges faced in the community setting when it comes to chimeric antigen receptor T-cell therapy (CAR T) and the best practices implemented to mitigate these challenges.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- From the community perspective, what are the main operational challenges faced when it comes to CAR T?
- What best practices have you/your practice implemented to mitigate these challenges?
Advertisement
Related to this article
Readers share their opinions on some of the most talked-about breast cancer abstracts they’re looking forward to seeing at ESMO 2026.
The FDA granted fast track designation to opamtistomig for first-line treatment of advanced or metastatic biliary tract cancer.
Roswell Park Comprehensive Cancer Center has earned national recognition in 2026 from the American Medical Association as a Joy in Medicine organization.
A planned interim analysis of the radiopharmaceutical RYZ101 showed improved PFS by blinded independent central review vs standard of care.
Conditional approvals in Armenia cover botensilimab plus balstilimab indicated for patients with MSS mCRC without active liver metastases.
The top 5 OncLive TV videos of the week.
Check out this September recap of OncLive’s coverage of the top news and expert insights in gastrointestinal cancers.
The FDA approved atezolizumab plus chemo for stage III colon cancer, cleared a tucatinib-based maintenance regimen for advanced breast cancer, and more.
Advertisement
Advertisement
Trending on OncLive
1
Dr Fradley on Real-World Atrial Fibrillation and Cardiovascular Outcomes in CLL
2
Five Under 5: Top Oncology Videos for the Week of 10/5/2026
3
Armenia Grants First Marketing Authorizations to Botensilimab Plus Balstilimab in Previously Treated MSS mCRC
4
RYZ101 Meets Primary PFS End Point in Phase 3 ACTION-1 Trial for Post–Lutetium-177 GEP-NETs
5